April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Biosynthetic Corneas - Evaluation in Humans
Author Affiliations & Notes
  • P. Fagerholm
    Dept of Ophthal, Linkoping University, Linkoping, Sweden
  • N. Lagali
    Dept of Ophthal, Linkoping University, Linkoping, Sweden
  • M. Griffith
    Eye Institute, University of Ottawa, Ottawa, Ontario, Canada
  • Footnotes
    Commercial Relationships  P. Fagerholm, None; N. Lagali, None; M. Griffith, Patent,licensing, P.
  • Footnotes
    Support  Swedish Medichal Research Council, County Council of Östergötland, Sweden
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1508. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Fagerholm, N. Lagali, M. Griffith; Biosynthetic Corneas - Evaluation in Humans. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1508.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate biosynthetic constructs as substitutes for donor corneas in deep lamellar corneal grafting

Methods: : Collagen-based biosynthetic corneas designed to mimic the extracellular matrix of the corneal stroma have been developed and extensively evaluated in a range of animal models over the last 7 years. Recombinant human collagen type III (RHC III) was crosslinked with watersoluble carbodiimides and fabricated into optically, corneal substitutes for transplantation. Following study approval of the Medical Product Agency, Sweden and the Human Ethics Committee, University of Linköping, Sweden ,a Phase I study was initiated. 10 patients who were scheduled for corneal grafting were enrolled into the study. Nine had keratoconus and one had a deep scar following Pseudomonas keratitis.A central 6 mm in diameter deep lamellar button was excised and was replaced by a 6.25 mm in diameter 500 µm thick construct. Six overlying sutures were used to anchor the graft. Topical 0.1% dexamethasone and chloramphenicol was used for the first 1 month postoperatively. The sutures were removed after 5-7 weeks.The patients were followed clinically evaluated for UCVA, BSCVA and VA with contact lenses. Sensitivity (Bonnet-Cochet) and tear production (Schirmer ) were tested. Photography, OCT (Visante), topography (Orbscan II) and in vivo confocal microscopy (Heidelberg) was documented.

Results: : At 9 months, all patients had stably epithelialized and implants were anchored by keratocyte ingrowth. The BCVA was ≥ 20/ 40 in 6 patients and ≥ 20/200 in all patients.The mean central thickness was 416.7 µm (SD± 75.4 µm). The mean Schirmer values were 16.3 mm / 5 minutes (SD: ± 8.4) in the operated eyes and 17 mm/ 5 minutes(SD: ±9.3) in the fellow eye. The mean sensitivity was lower in the operated eye than in the control fellow eye. In-vivo confocal microscopy revealed beginning ingrowth of corneal nerves .

Conclusions: : Although the results at 1 year are yet to come, we nevertheless have shown for the first time that bioengineered collagen-based corneal substitutes are fully biocompatible and promote regeneration of corneal cells. They can be used as temporary patches , and in vitro studies show support of corneal limbal and endothelial cells . With further development and testing, such substitutes could be a complementary source of material for corneal transplantation.

Clinical Trial: : EudraCT nr:2006-006585-42

Keywords: cornea: clinical science • transplantation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.